公开(公告)号：US09611244B2

公开(公告)日：2017-04-04

申请号：US15148210

申请日：2016-05-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Hiroshi Nara ,  Nobuyuki Negoro

IPC: C07D317/72 ,  C07C317/12 ,  C07D309/28 ,  C07C317/44 ,  C07C317/46

CPC classification number: C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like.The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

公开(公告)号：US09533966B2

公开(公告)日：2017-01-03

申请号：US15175292

申请日：2016-06-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Hiroshi Nara ,  Nobuyuki Negoro

IPC: C07D317/72

CPC classification number: C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

Abstract translation: （其中，在说明书中更详细地说明每个符号）。

公开(公告)号：US08598226B2

公开(公告)日：2013-12-03

申请号：US13910374

申请日：2013-06-05

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tsuneo Yasuma ,  Nobuyuki Negoro

IPC: A61K31/343

CPC classification number: C07D409/12 ,  C07D307/80

Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

Abstract translation: 本发明提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。 化合物或其盐或其前药具有GPR40受体功能调节作用，并且可用作胰岛素促分泌素或用于预防或治疗糖尿病等的药剂。

公开(公告)号：US10738004B2

公开(公告)日：2020-08-11

申请号：US16331962

申请日：2017-09-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Nobuyuki Negoro ,  Masashi Yamasaki ,  Takahiro Tanaka ,  Naomi Kitamoto

IPC: C07C317/46 ,  A61K31/235 ,  A61P1/16 ,  A61P9/10 ,  A61P37/02 ,  A61P29/00 ,  A61P25/02 ,  A61P43/00

Abstract: Provided is a compound, such as ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl) -3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof, having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI).

公开(公告)号：US09828357B2

公开(公告)日：2017-11-28

申请号：US15356906

申请日：2016-11-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Toshitake Kobayashi ,  Morihisa Saitoh ,  Yasufumi Wada ,  Hiroshi Nara ,  Nobuyuki Negoro ,  Taisuke Katoh ,  Masashi Yamasaki ,  Takahiro Tanaka ,  Naomi Kitamoto

IPC: C07D317/72 ,  C07C317/12 ,  C07D309/28 ,  C07C317/44 ,  C07C317/46

CPC classification number: C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.

公开(公告)号：US20160159808A1

公开(公告)日：2016-06-09

申请号：US14907139

申请日：2014-07-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masanori Kawasaki ,  Satoshi Mikami ,  Shinji Nakamura ,  Nobuyuki Negoro ,  Shuhei Ikeda ,  Izumi Nomura ,  Tomoko Ashizawa ,  Toshihiro Imaeda ,  Masaki Seto ,  Shigekazu Sasaki ,  Shogo Marui ,  Takahiko Taniguchi

IPC: C07D487/04 ,  C07D498/08 ,  C07D491/08 ,  C07D471/04 ,  C07D473/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D473/00 ,  C07D491/08 ,  C07D498/08

Abstract: A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.

Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书所述，或其盐具有PDE2A抑制作用，并且可用作精神分裂症，阿尔茨海默氏病等的预防或治疗药物。